The U.S. Patent and Trademark Office granted Theranos, a biotech company that shuttered last year, five patents in March and April, CB Insights reports.
The patents were filed in 2015 and 2016, after the company came under fire for deceiving investors and the public about the readiness of its technology. They include a system to improve collection and testing of bodily fluids, a method to transport small-volume samples, a process that agitates particles to identify pathogens in samples, a process that can disrupt cells in fluids, and an accelerated red blood cell test.
Theranos has been granted more than 70 patents since 2003. However, Theranos was unable to deliver on its promise to create micro-blood tests that worked.
Its founder and former CEO, Elizabeth Holmes, was charged with 11 criminal felony counts and could face prison time.
Read more here.
More articles on health IT:
Google's 5 latest health-related job openings
Amazon, Microsoft finalists in DOD's $10B cloud computing deal
Organizations largely unprepared to deal with a cyberattack, survey finds